Sex-specific molecular signatures in persistent pain after whiplash injury: an exploratory analysis

PAIN Reports · Published 2026-07-31 · DOI 10.1097/pr9.0000000000001479

Free full text

Authors (5)

Joel Fundaun, Colette Ridehalgh, Andrew Dilley, Annina B. Schmid, Georgios Baskozos

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Fundaun, J., Ridehalgh, C., Dilley, A., et al. (2026). Sex-specific molecular signatures in persistent pain after whiplash injury: an exploratory analysis. PAIN Reports. https://doi.org/10.1097/pr9.0000000000001479

Related articles

• Caregivers' perceptions, knowledge, and perceived barriers to pediatric procedural pain management: a cross-sectional study · PAIN Reports · 2026 · Same journal
• Motor deficits after herpes zoster: a comparative analysis of patient characteristics and sensory changes · PAIN Reports · 2026 · Same journal
• Voluntary wheel running decreases intraepidermal nerve fibers in healthy mice · PAIN Reports · 2026 · Same journal
• Validation of a self-report measure for diagnostic screening and assessment in complex regional pain syndrome · PAIN Reports · 2026 · Same journal
• Do partner handholding effects linger? Order effects of handholding support on mechanical hypersensitivity in women · PAIN Reports · 2026 · Same journal
• Electroencephalography during acute painful procedures in neonates: a scoping review · PAIN Reports · 2026 · Same journal
• Youth experiences with discrimination and the association with multisite pain · PAIN Reports · 2026 · Same journal
• Neuronal metabolism role in ketogenic diet improvements in bortezomib-induced painful peripheral neuropathy mouse model · PAIN Reports · 2026 · Same journal
• Trajectories of school absenteeism in adolescents with recurrent pain: predictors and distal outcomes · PAIN Reports · 2026 · Same journal
• Safety and tolerability of KLS-2031 in lumbosacral radiculopathy–induced neuropathic pain: randomized, placebo-controlled phase 1/2a trial · PAIN Reports · 2026 · Same journal